Matthew M Seavey

Summary

Publications

  1. ncbi The many faces of Janus kinase
    Matthew M Seavey
    Cephalon, Inc, Drug Discovery Research, 145 Brandywine Parkway, West Chester, PA 19380, USA
    Biochem Pharmacol 83:1136-45. 2012
  2. ncbi Immunoregulation of fetal and anti-paternal immune responses
    Matthew M Seavey
    David H Smith Center for Vaccine Biology and Immunology and the Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Immunol Res 40:97-113. 2008
  3. ncbi A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
    Kristine L Stump
    Cephalon, Inc, Research Drug Discovery, 145 Brandywine Parkway, Building 200, West Chester, PA 19380 4249, USA
    Arthritis Res Ther 13:R68. 2011
  4. ncbi Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer
    Matthew M Seavey
    Cephalon, Inc, Worldwide Discovery Research, West Chester, PA 19380, USA
    Mol Cancer Ther 11:984-93. 2012
  5. ncbi Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
    Matthew M Seavey
    Cephalon, Inc, Worldwide Discovery Research, 145 Brandywine Parkway, West Chester, PA 19380 4249, United States
    Int Immunopharmacol 12:257-70. 2012
  6. ncbi Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2
    Lily D Lu
    Cephalon, Inc, Worldwide Discovery Research, West Chester, PA 19380, USA
    J Immunol 187:3840-53. 2011
  7. ncbi Estradiol-induced vaginal mucus inhibits antigen penetration and CD8(+) T cell priming in response to intravaginal immunization
    Matthew M Seavey
    David H Smith Center for Vaccine Biology and Immunology, and the Department of Microbiology and Immunology, University of Rochester Medical Center, NY 14642, United States
    Vaccine 27:2342-9. 2009
  8. ncbi Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery
    Matthew M Seavey
    Worldwide Discovery Research, Cephalon, Inc, West Chester, Pennsylvania, USA
    Curr Protoc Pharmacol . 2011
  9. ncbi Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology
    Lily D Lu
    Worldwide Discovery Research, Cephalon, Inc, West Chester, Pennsylvania 19380, USA
    BMC Immunol 11:55. 2010
  10. ncbi Paternal antigen-bearing cells transferred during insemination do not stimulate anti-paternal CD8+ T cells: role of estradiol in locally inhibiting CD8+ T cell responses
    Matthew M Seavey
    David H. Smith Center for Vaccine Biology and Immunology, and Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Immunol 177:7567-78. 2006

Collaborators

Detail Information

Publications10

  1. ncbi The many faces of Janus kinase
    Matthew M Seavey
    Cephalon, Inc, Drug Discovery Research, 145 Brandywine Parkway, West Chester, PA 19380, USA
    Biochem Pharmacol 83:1136-45. 2012
    ..In addition, it will review current paradigms in the field and treatment programs which could be complemented by small molecule inhibitors of Janus kinase...
  2. ncbi Immunoregulation of fetal and anti-paternal immune responses
    Matthew M Seavey
    David H Smith Center for Vaccine Biology and Immunology and the Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Immunol Res 40:97-113. 2008
    ..It's the intricate communication and interplay between the immune system and the endocrine system that will ultimately decide the success or fate of the developing fetus...
  3. ncbi A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
    Kristine L Stump
    Cephalon, Inc, Research Drug Discovery, 145 Brandywine Parkway, Building 200, West Chester, PA 19380 4249, USA
    Arthritis Res Ther 13:R68. 2011
    ..In this paper, we describe the efficacy profile of CEP-33779, a highly selective, orally active, small-molecule inhibitor of JAK2 evaluated in two mouse models of RA...
  4. ncbi Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer
    Matthew M Seavey
    Cephalon, Inc, Worldwide Discovery Research, West Chester, PA 19380, USA
    Mol Cancer Ther 11:984-93. 2012
    ....
  5. ncbi Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
    Matthew M Seavey
    Cephalon, Inc, Worldwide Discovery Research, 145 Brandywine Parkway, West Chester, PA 19380 4249, United States
    Int Immunopharmacol 12:257-70. 2012
    ..Treatment of lupus in these models demonstrated that delanzomib treatment lead to greater tolerability and rate of response resulting in improved stabilization of disease...
  6. ncbi Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2
    Lily D Lu
    Cephalon, Inc, Worldwide Discovery Research, West Chester, PA 19380, USA
    J Immunol 187:3840-53. 2011
    ..These data support the possibility of using potent, orally active, small-molecule inhibitors of JAK2 to treat the debilitative disease SLE...
  7. ncbi Estradiol-induced vaginal mucus inhibits antigen penetration and CD8(+) T cell priming in response to intravaginal immunization
    Matthew M Seavey
    David H Smith Center for Vaccine Biology and Immunology, and the Department of Microbiology and Immunology, University of Rochester Medical Center, NY 14642, United States
    Vaccine 27:2342-9. 2009
    ..The estradiol-induced mucus barrier may thus prevent exposure to antigens delivered intravaginally, supplementing additional estradiol-dependent mechanism(s) that inhibit CD8(+) T cell priming after insemination or vaginal vaccination...
  8. ncbi Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery
    Matthew M Seavey
    Worldwide Discovery Research, Cephalon, Inc, West Chester, Pennsylvania, USA
    Curr Protoc Pharmacol . 2011
    ..The reader will acquire a working knowledge of what models are available and the potential advantages and disadvantages of each, including ex vivo assays relevant to the discovery of new SLE therapeutics...
  9. ncbi Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology
    Lily D Lu
    Worldwide Discovery Research, Cephalon, Inc, West Chester, Pennsylvania 19380, USA
    BMC Immunol 11:55. 2010
    ....
  10. ncbi Paternal antigen-bearing cells transferred during insemination do not stimulate anti-paternal CD8+ T cells: role of estradiol in locally inhibiting CD8+ T cell responses
    Matthew M Seavey
    David H. Smith Center for Vaccine Biology and Immunology, and Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Immunol 177:7567-78. 2006
    ....